4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Liver Fibrosis by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 360 ongoing clinical trials involving Liver Fibrosis
Of the 360 trials,193 trials are in Phase II
Furthermore, 76 trials are in Phase II/III

Number of ongoing Clinical Trials (for drugs) involving Liver Fibrosis by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Liver Fibrosis, a Gastrointestinal Indication. Asia-Pacific, North America and Europe are some of the prominent regions engaged in Liver Fibrosis-related drug trials.

Liver Fibrosis related clinical trial sponsors

Sun Yat-Sen University Hospital 3, Bristol-Myers Squibb Co, NGM Biopharmaceuticals Inc, and Novartis AG are some of the notable clinical trial sponsors involved in Liver Fibrosis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Liver Fibrosis

Entecavir, and Tricholine citrate (Livodex) are among the key marketed drugs involving Liver Fibrosis.

Entecavir is a nucleoside analog acts as an antiviral agent. It functions via Hepatitis B Virus DNA Polymerase (Hepatitis B Virus Reverse Transcriptase or Hepatitis B Virus Ribonuclease H or EC 2.7.7.7 or EC 2.7.7.49 or EC 3.1.26.4) Inhibitor mechanism of action. It is formulated as film coated tablets for oral route of administration. Entecavir is indicated for the treatment of adult patients with chronic infection with hepatitis B virus (hbv) compensated liver disease with evidence of active viral replication, persistent elevation of serum alanine aminotransferase (alt) levels, histologically proven active liver inflammation and / or fibrosis, decompensated liver disease, for compensated and decompensated liver diseases. It is also indicated for the treatment of chronic HBV infection in pediatric nucleoside-treated patients aged 2 years to less than 18 years with compensated liver disease with evidence of active viral replication and persistent elevation of serum alt levels, or moderate to severe hepatic inflammation and / or histologically proven fibrosis. Entecavir was first approved in 2017 and is marketed in France by Cristers SAS.

Tricholine citrate (Livodex) is a lipotropic and hepato-protective agent. It is formulated as syrup for oral route of administration. Livodex is indicated for the treatment of fatty infiltration and cirrhosis of liver, post-hepatic convalescence, hepatomegaly, hepatic cholestasis, chronic hepatic insufficiency, atonic constipation and loss of appetite, treatment and prophylaxis of drug induced liver damage and alcoholism. Livodex is marketed in India by Ikon Remedies Pvt Ltd.